PrEP

Antiretroviral therapy may not be entirely effective in restoring the immune protection resulting from viral infections or childhood vaccines received prior to becoming HIV-positive.

The findings support the inclusion of these patient populations in ICI-based clinical trials and treatment.

Hospitalization offers unique opportunities to engage out-of-care individuals with the ultimate goal of improving their HIV outcomes and reducing health disparities.

The app takes the authoritative, evidence-based 2015 World Health Organization pre-exposure prophylaxis guidelines and adapts for a mobile device.

Top news of the day from across the health care landscape.

The loss of immunity, also referred to as “HIV-associated immune amnesia,” could be related to why people with HIV who are on ART still have shorter lives on average than people without HIV, the study noted.

Dosing based around the frequency of sexual activity provides adequate protection for men vulnerable to HIV infection.

Study shows a high burden of sexually transmitted infections among both individuals starting and persistently using PrEP.

Among eligible MSM, PrEP use is associated with lower levels of HIV anxiety, a mental health benefit that could be incorporated into initiatives that aim to increase uptake.

Through the Ready, Set, PrEP program, qualified patients from across the United States can access PrEP medication for the prevention of HIV, for free.

Program allows women in sub-Saharan Africa who visited any of 16 different maternal-child health centers to receive a behavioral assessment designed to provide information about HIV risk, learn about PrEP, and obtain a prescription for PrEP, if desired.

Researchers investigate whether on-demand pre-exposure prophylaxis was similarly effective among individuals with lower exposure to HIV risk.

A study sought to determine how HIV avoids the antiviral protein, zinc-finger antiviral protein.

A study used sequence-based methods to identify specific virus characteristics that may help determine efficacy of antibody therapies in HIV.

The CDC reported progress with the current status of the 3 strategies within the national initiative, Ending the HIV Epidemic: A Plan for America.

A report suggests that addressing financial barriers to antiretroviral therapy adherence may improve levels of viral suppression.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The FDA has approved Descovy (emtricitabine 200-mg and tenofovir alafenamide 25-mg tablets) for HIV-1 pre-exposure prophylaxis (PrEP).

National Institutes of Health experts discuss optimization of existing strategies for HIV treatment and prevention, as well as the development of new approaches.

California has passed SB 159, becoming the first state allowing pharmacists to dispense HIV prevention pills to patients without a doctor’s prescription. Supporters say the legislation will greatly reduce the spread of infection.1

TIN Rx is aiming to serve the most vulnerable populations, including LGBTQ patients, homeless patients, and others who may typically face stigma in pharmacies.

Top news of the day from across the health care landscape.

The FDA has approved emtricitabine 200 mg and tenofovir alafenamide 25 mg (Descovy, Gilead Sciences Inc.) as a second pre-exposure prophylaxis drug in at-risk adults and adolescents weighing at least 75 Ib.

London Mayor Sadiq Khan has called for broader availability of pre-exposure prophylaxis drugs in his welcoming speech at the Fast-Track Cities 2019 conference, where leaders from 300 cities around the world will discuss municipal responses to HIV, tuberculosis, and viral hepatitis.

In recent months, legislation to increase access to pre- and post-exposure prophylaxis (PrEP and PEP) passed in California with a vote of 34-1 in the Senate and a unanimous vote in the Assembly.

An FDA committee has recommended approval of Gilead’s Descovy to reduce the risk of sexually acquired HIV infection in those at high risk of acquiring the virus.

An FDA committee voted 16 to 2 to recommended emitricitabine 200 mg and tenofovir alafenamide 25 mg tablets (Descovy, Gilead) for a HIV pre-exposure prophylaxis indication.

Pre-exposure prophylaxis (PrEP) can reduce the risk of HIV infection in individuals at high risk.

Top news of the day from across the health care landscape.